[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Asavamongkolkul A, Pimolsanti R, Waikakul S, Kiatsevee P: Periacetabular limb salvage for malignant bone tumours. J Orthop Surg (Hong Kong); 2005 Dec;13(3):273-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periacetabular limb salvage for malignant bone tumours.
  • PURPOSE: To evaluate treatment outcomes in primary malignant periacetabular bone tumour removal and limb salvage with or without bone-graft reconstruction.
  • METHODS: A total of 13 patients were treated for malignant periacetabular bone tumours at Siriraj Hospital, Bangkok, Thailand.
  • The diagnoses were chondrosarcoma (n=8), Ewing's sarcoma (n=2), osteosarcoma (n=1), well-differentiated osteosarcoma (n=1), and malignant giant cell tumour (n=1).
  • 11 patients did not undergo reconstruction following tumour resection; 2 patients received fibular bone grafts bridging the periacetabulum to the remaining sacrum.
  • Adjuvant chemotherapy was administered for high-grade malignant tumours, and postoperative radiation therapy was performed on patients with a closed surgical margin.
  • According to the Musculoskeletal Tumor Society classification system, the mean functional analysis at final follow-up was 68.7%.
  • CONCLUSION: Malignant periacetabular tumours are difficult to manage.
  • Functional results of our patients with no reconstruction or with bone-graft bridging were fair.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage. Pelvic Bones
  • [MeSH-minor] Adult. Bone Transplantation. Chemotherapy, Adjuvant. Child. Chondrosarcoma / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Giant Cell Tumor of Bone / therapy. Humans. Male. Middle Aged. Osteosarcoma / therapy. Sarcoma, Ewing / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365491.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Hashimoto K, Hatori M, Hosaka M, Watanabe M, Hasegawa T, Kokubun S: Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: a case report and review of the literature. Tohoku J Exp Med; 2006 Feb;208(2):157-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: a case report and review of the literature.
  • Giant cell tumor of the bone (GCT) is a relatively uncommon tumor.
  • It is characterized by the presence of multinucleated giant cells.
  • GCT is a primary benign tumor but may evolve into a malignant tumor, usually after irradiation.
  • We report a rare case of osteosarcoma arising ten years after the primary surgery for GCT without radiation.
  • Roentgenogram revealed a bone tumor in the lateral femoral condyle of the right knee.
  • Histopathological examination demonstrated the features of GCT, and treatment consisted of curettage and bone grafting.
  • Ten years after the primary treatment, severe knee pain recurred.
  • Histopathological examination demonstrated a lacy pattern of osteoids and abnormal mitoses in the aggregated atypical mononuclear cells, indicating osteosarcoma.
  • Despite above-knee amputation and chemotherapy, scapular and lung metastases developed and the patient died five months after above knee amputation.
  • One may question whether the primary GCT contained some malignant cells.
  • However, given the aggressiveness of the malignant tumor, this is unlikely.
  • The recurrence of pain and aggravation of bone destruction many years after the primary treatment suggest malignant transformation of GCT.
  • [MeSH-major] Bone Neoplasms / complications. Giant Cell Tumors / complications. Neoplasms, Second Primary. Osteosarcoma / etiology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434839.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Shi SF, Dong Y, Zhang CL, Bao K, Ma XJ: [Prosthesis replacement of the proximal humerus after the resection of bone tumors]. Chin J Cancer; 2010 Jan;29(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prosthesis replacement of the proximal humerus after the resection of bone tumors].
  • BACKGROUND AND OBJECTIVE: After chemotherapy was used to treat patients with malignant bone tumors in 1970s, amputation, which was the typical intervention in the 1980s, has been substituted with limb-sparing surgery.
  • This article reported the surgical indications, operative methods, operative effects, and complications of prosthetic replacement of the proximal humerus after the resection of bone tumors.
  • METHODS: From April 2004 and December 2008, prosthetic replacement was performed in 18 patients with proximal humerus tumors, including 7 patients with osteosarcoma, 5 patients with chondrosarcoma, 3 patients with giant cell tumor (GCT) of the bone, 1 patient with GCT of the bone combined with an aneurysmal bone cyst, and 1 patient with metastatic bone tumors.
  • The patient with metastatic bone tumors reported severe pain.
  • RESULTS: The follow-up ranged 5-61 months (mean, 29 months) and showed that 1 patient with osteosarcoma died 19 months after surgery.
  • According to the functional score developed by the International Society of Limb Salvage, scores ranged between 18 and 29 points, with an average of 24 points.
  • CONCLUSIONS: The prosthesis replacement for the patients with bone tumors in the proximal humerus is an appropriate procedure with satisfactory therapeutic outcomes; however, many complications should be noted and long-term therapeutic effect needs further investigations.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. Humerus. Osteosarcoma / surgery. Prosthesis Implantation
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement. Female. Follow-Up Studies. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / surgery. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Range of Motion, Articular. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Nishizawa K, Nakamura E, Kobori G, Kobayashi T, Yamamoto S, Kamoto T, Okuno H, Terai A, Kakehi Y, Ogawa O, Ueda H, Yamaoka T, Kadowaki N: [A case of giant perirenal malignant lymphoma: a case report]. Hinyokika Kiyo; 2002 Mar;48(3):175-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of giant perirenal malignant lymphoma: a case report].
  • We report a case of malignant lymphoma arising as a giant perirenal mass in a 62-year-old woman who presented with an enlarging abdominal mass.
  • Computed tomography (CT) revealed a large homogeneous mass with a diameter of 20 cm arising in the retroperitoneum.
  • Compared with the renal cortex, the tumor showed a homogeneous isodense mass by plain CT and only slight enhancement by the contrast-enhanced CT.
  • On the basis of these imaging studies, the tumor was diagnosed as lymphoma.
  • Then, a US guided percutaneous biopsy was performed and the tumor was diagnosed as malignant B-cell lymphoma by the histopathological analysis.
  • This patient was treated by systemic chemotherapy since tumor cells were also disseminated in the bone marrow.
  • The tumor responded well to the chemotherapy and about 70% of regression was achieved after six courses of chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Kidney / pathology. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11993214.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, Heymann D: Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer; 2005;5:123
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.
  • BACKGROUND: Osteosarcoma is the most common type of primary bone tumor.
  • The use of aggressive chemotherapy has drastically improved the prognosis of the patients with non-metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor.
  • Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are needed.
  • Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor development and already assessed with success for the treatment of several cancers including melanoma.
  • While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma.
  • METHODS: Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor, chondrosarcoma, plasmocytoma and bone metastases).
  • Similar experiments were performed using rat osteosarcoma model.
  • RESULTS: While TIL with a main CD4+ profile were easily isolated from most of the tumor samples, only TIL extracted from osteosarcoma were cytotoxic against allogeneic tumor cells.
  • Similar data were observed in rat osteosarcoma model where TIL were characterized by a main CD4+ profile and high lytic activity against allogeneic and autologous tumor cells.
  • Moreover, rat TIL expansion was not accompanied by refractoriness to further activation stimulus mainly by tumor antigens.
  • CONCLUSION: These results demonstrated that TIL therapy could be a very efficient strategy for the treatment of adult osteosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphocytes / pathology. Osteolysis. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. CD4-Positive T-Lymphocytes / cytology. Cell Line, Tumor. Disease Models, Animal. Female. Flow Cytometry. Humans. Immunotherapy / methods. Leukocytes / pathology. Lymphocytes, Tumor-Infiltrating / cytology. Male. Melanoma / pathology. Middle Aged. Neoplasm Metastasis. Phenotype. Prognosis. Rats

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1999 Nov;12(11):1050-6 [10574602.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):451-8 [16034562.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):29-32 [10853014.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Jul-Aug;17(5):355-64 [10914045.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Orthop Res. 2001 May;19(3):346-51 [11398844.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):963-70 [11549589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 [11734652.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3950-62 [11751487.001]
  • [Cites] Cancer Immunol Immunother. 2002 Nov;51(10):539-46 [12384805.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):53-7 [14736523.001]
  • [Cites] Intern Med. 2004 Apr;43(4):323-6 [15168777.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5442-8 [15289353.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Int J Cancer. 1977 Jul 15;20(1):112-9 [269099.001]
  • [Cites] Science. 1986 Sep 19;233(4770):1318-21 [3489291.001]
  • [Cites] J Biol Response Mod. 1990 Apr;9(2):149-59 [1971302.001]
  • [Cites] Eur J Immunol. 1991 Jun;21(6):1403-10 [1904359.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):932-7 [2067036.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Cancer Immunol Immunother. 1992;34(4):241-51 [1311218.001]
  • [Cites] Cancer Immunol Immunother. 1994 May;38(5):332-8 [8162615.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] Immunol Rev. 1995 Jun;145:167-77 [7590825.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):580-7 [8915492.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Orthop Res. 1997 Jan;15(1):128-32 [9066537.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):543-7 [9352689.001]
  • [Cites] Pathol Res Pract. 1998;194(10):679-84 [9820863.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1137-42 [10368665.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):721-6 [10505031.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):730-7 [15665620.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):2026-34 [15753403.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):258-67 [15838383.001]
  • [Cites] J Immunol. 2005 May 15;174(10):5959-67 [15879088.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1754-63 [15902685.001]
  • [Cites] Oncol Rep. 2005 Sep;14(3):763-9 [16077989.001]
  • [Cites] Tumori. 2000 Jan-Feb;86(1):46-52 [10778766.001]
  • (PMID = 16188028.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1262697
  •  go-up   go-down


6. Hornicek FJ, Gebhardt MC, Tomford WW, Sorger JI, Zavatta M, Menzner JP, Mankin HJ: Factors affecting nonunion of the allograft-host junction. Clin Orthop Relat Res; 2001 Jan;(382):87-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonunion of allograft-host junction after bone transplantation is not uncommon, and its treatment frequently is problematic.
  • To improve the understanding of these nonunions, a retrospective review was performed of 163 nonunions in 945 patients who underwent allograft transplantation (17.3%) for various benign and malignant tumors at the authors' institution between 1974 and 1997.
  • Of these 945 patients, 558 did not receive adjuvant therapy.
  • Chemotherapy was administered to 354 patients and only 33 patients received radiation therapy alone.
  • Seventy-one patients had radiation treatment and chemotherapy.
  • In 108 patients, treatment was successful resulting in union of the allograft-host junction.
  • Forty-nine patients did not respond to multiple surgical treatment attempts.
  • The rate of nonunions increased to 27% for the patients who received chemotherapy as compared with 11% for the patients who did not receive chemotherapy.
  • [MeSH-major] Bone Transplantation / physiology. Bone and Bones / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Arthrodesis. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / surgery. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Chondrosarcoma / surgery. Female. Follow-Up Studies. Fractures, Bone / etiology. Giant Cell Tumor of Bone / surgery. Graft Survival. Humans. Joints / surgery. Male. Middle Aged. Osteosarcoma / surgery. Proportional Hazards Models. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Sarcoma, Ewing / surgery. Surgical Wound Infection / etiology. Transplantation, Homologous. Treatment Outcome. Wound Healing

  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11154010.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D: Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des; 2010;16(27):2981-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approach of primary bone tumours by bisphosphonates.
  • Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas.ii)and giant cell tumour and bone metastases originate from others cancer (Breast, prostate, kidney cancer, etc).
  • However, the first step of bone tumour development is associated with an induction of bone resorption and the establishment of a vicious cycle between the osteoclasts and the tumour growth.
  • Indeed, bone resorption contributes to the pathogenesis of bone tumour by the release of cytokines (IL6, TNFα) which govern the bone tumour's development and which are trapped into the bone matrix.
  • Bisphosphonates (BPs) are chemical compounds of P-C-P structure with a high affinity for bone hydroxyapatite crystals.
  • Thus, they have been used as a carrier for radio nucleotides to develop novel approaches of bone imaging.
  • BPs exert also indirect anti-tumour activities in vivo.
  • Indeed, BPs directly interfere with the bone microenvironment and target osteoclasts, endothelial cells and immune cells (tumour-associated macrophages, γ9δ2 T cells).
  • BPs induce tumour cell death in vitro and same activity is suspected in vivo.
  • The present review summarizes the mechanisms of actions of BPs as well as their clinical interests in bone primary tumours.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Diphosphonates / pharmacology. Diphosphonates / therapeutic use. Drug Design
  • [MeSH-minor] Animals. Bone Density Conservation Agents / pharmacology. Bone Density Conservation Agents / therapeutic use. Chondrosarcoma / drug therapy. Giant Cell Tumor of Bone / drug therapy. Humans. Osteosarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722622.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


8. Guo W, Yang RL, Tang XD, Tang S, Li DS, Yang Y: [Resection and reconstruction for primary pelvic tumors around acetabular]. Zhonghua Wai Ke Za Zhi; 2004 Dec 7;42(23):1419-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve patients were diagnosed with chondrosarcoma, 1 with Ewing sarcoma, 3 with osteosarcoma, 1 with lymphoma, 1 with carcinosarcoma, 1 with malignant fibrohistiocytoma (MFH), 2 with myeloma, 9 with giant cell tumor (GCT), 1 with aneurysmal bone cyst.
  • Among 31 patients with peri-acetabular tumors, 8 were reconstructed with hemi-pelvic prosthesis, 7 with saddle prosthesis, 6 with cauterized tumor bone and total hip arthroplasty, 10 with total hip replacement after curettage of lesion and cemented.
  • RESULTS: Among 21 patients who underwent tumor resection and reconstruction in region II, 6 had local relapse.
  • Two of 3 patients with osteosarcoma were dead.
  • Twenty-one patients with acetabular reconstruction after resection of lesions in region II could sit and stand normally and walked with a cane, several of which even had normal gait.
  • We must pay more attention on the following points in the surgical treatment of periacetabular tumors:.
  • (3) The reconstructed acetabulum is unstable, so the patients must stand with a cane to protect the reconstructed hip joint;.
  • (5) Surgical treatment of pelvic tumors would easily result in poor wound healing especially in the patients receiving chemotherapy or radiotherapy because of extensive soft tissue stripping.
  • The destroyed soft tissue caused by chemotherapy or radiotherapy may increase the great tissue tension after implantation of allograft.

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733453.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • All patients presented with a solitary mass, ranging in size from 1.8 to 12 cm (median 6.8 cm).
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Binucleated cells were common, and 6 cases contained tumor giant cells.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.
  • Histiocytic sarcoma has the potential for an aggressive clinical course, most often with lymph node involvement.
  • Tumor size may be a prognostic factor.
  • [MeSH-major] Sarcoma / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM: Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol; 2001 Jun;25(6):699-709
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor.
  • Sclerosing epithelioid fibrosarcoma (SEF) is an uncommon tumor of deep soft tissues, originally described in 1995 by Meis-Kindblom et al.
  • The group consisted of six male and 10 female patients (age range, 14-55 years; mean age, 40 years), and the tumors were located in a limb or limb girdle (n = 7), base of the penis (n = 1), back or chest wall (n = 3), and head and neck (n = 5).
  • Tumor size ranged from 3.7 to 22 cm (mean, 8.9 cm).
  • Histologically, the SEFs were composed predominantly of small to moderate-size round to ovoid, relatively uniform cells, often with clear cytoplasm, embedded in a hyalinized fibrous stroma.
  • The only consistent immunohistochemical finding was a strong, diffuse reactivity of tumor cells for vimentin.
  • Bone invasion and tumor necrosis, features not reported before, were found in six cases each.
  • Treatment consisted of intralesional excision (n = 2), attempted wide local excision (n = 11), and amputation (n = 3), with either adjuvant radiation therapy (n = 9) or chemotherapy (n = 3).
  • Eight patients (57%) died of disease 16 to 86 months after diagnosis.
  • SEF shares some pathologic features with two other fibrosing fibrosarcomas, low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes, but in the authors' experience behaves clinically as a fully malignant sarcoma.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395547.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Mankin HJ, Gunnoe J, Farid Y, Hornicek FJ, Gebhardt MC: Long-term effects of connective tissue cancer treatment. Clin Orthop Relat Res; 2004 Sep;(426):74-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of connective tissue cancer treatment.
  • In 1999, we began a study to assess the long-term effect of connective tissue cancer treatment on clinical, social, and psychologic aspects of the lives of surviving patients.
  • A specially designed computer program generated an 85-item questionnaire, which was sent to more than 2000 patients with malignant bone and soft tissue neoplasms.
  • Although there are many possible uses for these data, we chose to do a study comparing the lifestyle and physical and sociologic problems for 144 patients treated with chemotherapy and surgery for high-grade osteosarcoma against a control population consisting of 61 patients treated surgically for benign giant cell tumors of bone.
  • The data show a remarkable degree of compensation on the part of the patients with the malignant tumors in terms of some problems but some significant differences particularly in physical status and functional limitations.
  • [MeSH-major] Bone Neoplasms / therapy. Giant Cell Tumor of Bone / therapy. Osteosarcoma / therapy
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Analgesics / therapeutic use. Body Weight. Disability Evaluation. Employment. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Quality of Life

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15346055.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


12. Chen W, Zhu H, Zhang L, Li K, Su H, Jin C, Zhou K, Bai J, Wu F, Wang Z: Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation. Radiology; 2010 Jun;255(3):967-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation.
  • PURPOSE: To evaluate the long-term follow-up results of ultrasonographically (US)-guided high-intensity focused ultrasound ablation in patients with primary bone malignancy.
  • From December 1997 to November 2004, 80 patients with a primary bone malignancy-60 with stage IIb disease and 20 with stage III disease (Enneking staging system)-were treated with US-guided high-intensity focused ultrasound ablation.
  • High-intensity focused ultrasound ablation combined with chemotherapy was performed in 62 patients with osteosarcoma, one patient with periosteal osteosarcoma, and three patients with Ewing sarcoma.
  • The remaining 14 patients had chondrosarcoma, giant cell bone cancer, periosteal sarcoma, or an unknown malignancy and were treated with high-intensity focused ultrasound ablation only.
  • Magnetic resonance (MR) imaging or computed tomography (CT), and single photon emission computed tomography (SPECT) were used to assess tumor response.
  • RESULTS: High-intensity focused ultrasound ablation guided by real-time US was performed.
  • Follow-up images demonstrated completely ablated malignant bone tumors in 69 patients and greater than 50% tumor ablation in the remaining 11 patients.
  • Among the patients with stage IIb disease, long-term survival rates were substantially improved in the 30 patients who received the full treatment-that is, complete high-intensity focused ultrasound and full cycles of chemotherapy-compared with the survival rates for the 24 patients who did not finish the chemotherapy cycles and the six patients who underwent partial ablation only.
  • CONCLUSION: US-guided high-intensity focused ultrasound ablation of malignant bone tumors is feasible and effective and eventually may be a component of limb-sparing techniques for patients with these cancers.
  • [MeSH-major] Bone Neoplasms / therapy. Ultrasonic Therapy / methods. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Prospective Studies. Survival Rate. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2010
  • (PMID = 20501734.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Smith SE, Keshavjee S: Primary chest wall tumors. Thorac Surg Clin; 2010 Nov;20(4):495-507
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of chest wall tumors is diverse, including both benign and malignant lesions (primary and malignant), local extension of adjacent disease, and local manifestations of infectious and inflammatory processes.
  • Primary chest wall tumors are best classified by their primary component: soft tissue or bone.
  • Work-up consists of a thorough history, physical examination and imaging to best assess location, size, composition, association with surrounding structures, and evidence of any soft tissue component.
  • Biopsies are often required, especially for soft tissue masses.
  • Treatment depends on histological subtype and location, but may include chemotherapy and radiotherapy in addition to surgical resection.
  • [MeSH-major] Bone Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Thoracic Neoplasms / surgery. Thoracic Wall
  • [MeSH-minor] Chondrosarcoma / surgery. Clavicle / surgery. Fibrous Dysplasia of Bone / surgery. Giant Cell Tumor of Bone / surgery. Histiocytosis, Langerhans-Cell / surgery. Humans. Osteochondroma / surgery. Reconstructive Surgical Procedures. Ribs / surgery. Sternum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974433.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


14. Puri A, Agarwal MG, Shah M, Srinivas CH, Shukla PJ, Shrikhande SV, Jambhekar NA: Decision making in primary sacral tumors. Spine J; 2009 May;9(5):396-403
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decision making in primary sacral tumors.
  • Appropriate decision making is crucial to obtain the best possible outcome in terms of maximizing disease control while attempting to minimize neurological dysfunction.
  • PURPOSE: Our study presents the results of a group of patients with primary tumors of the sacrum who were surgically treated by the same multidisciplinary team at a specialist oncology center over a relatively short period of time (5 years).
  • The diagnosis included chordoma in six patients, giant cell tumor in seven patients, aneurysmal bone cyst in two patients, and a chondrosarcoma and an osteoblastoma in one patient each.
  • None of the patients received chemotherapy.
  • The follow-up duration ranged from 18 to 44 months with a mean of 31 months.
  • Three of the four cases who received postoperative irradiation developed recurrence.
  • CONCLUSION: Wide resection with adequate margins gives the best chance of local control and should be the surgery of choice for all malignant primary sacral tumors and in benign lesions involving lower segments when preservation of both S3 roots is possible.
  • The administration of parenteral bisphosphonates may prove beneficial in cases of giant cell tumor managed with serial embolization.
  • [MeSH-minor] Adult. Child. Cooperative Behavior. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059810.001).
  • [ISSN] 1878-1632
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wang J, Chen A, Luo Y: [Surgical management of limb salvage for osteogenic malignant tumors around knees]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):975-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of limb salvage for osteogenic malignant tumors around knees].
  • OBJECTIVE: To probe a satisfactory surgical management of the limb salvage for osteogenic malignant tumors around the knees.
  • METHODS: From January 1989 to December 2001, 42 patients (19 males and 18 females, aged 12-46) with osteogenic malignant tumors around the knees underwent surgical management of the limb salvage, including prosthesis replacement, allogenous bone grafting, and bone cement with adriamycin filled.
  • Based on the pathological examination, osteosarcoma was found in 11 patients, synoviosarcoma in 4 patients, malignant fibrous histiocytoma in 3 patients, and giant cell tumor of the bone in 19 patients.
  • All the patients underwent neoadjuvant chemotherapy for 1-2 courses before operation except the patients with giant cell tumor of the bone.
  • The patients underwent prosthesis replacement, allogenous bone grafting, bone cement with adriamycin filled, and postoperative chemotherapy.
  • By the Enneking evaluating system, the patients were assessed on their reconstructed limb functions after the reconstructive operation for the musculoskeletal malignant tumors.
  • RESULTS: According to the follow-up for 3-11 years (mean, 5.6 years) in the 37 patients, 2 patients had recurrence and metastasis of the tumor, and died 3 and 4 years after operation, respectively.
  • One patient underwent amputation of the limb for local recurrence of the tumor.
  • Two patients had amputation of the limb for the rejection of the allogenous bone graft and the formation of the fistula.
  • CONCLUSION: Making an early diagnosis, recognizing the operative indication, choosing the operative method, and performing the preoperative and postoperative chemotherapy and/or radiotherapy are the keys to achieving an ideal limb-salvage surgery for osteogenic malignant tumors around the knees.
  • [MeSH-major] Knee Joint. Limb Salvage. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Giant Cell Tumor of Bone / surgery. Humans. Male. Middle Aged. Prosthesis Implantation. Reconstructive Surgical Procedures. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140066.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Mori Y, Tsuchiya H, Karita M, Nonomura A, Nojima T, Tomita K: Malignant transformation of a giant cell tumor 25 years after initial treatment. Clin Orthop Relat Res; 2000 Dec;(381):185-91
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a giant cell tumor 25 years after initial treatment.
  • The current authors report a patient in whom a malignant fibrous histiocytoma developed long after a benign giant cell tumor of bone was removed from the same site.
  • Twenty-five years after a benign giant cell tumor of the lateral condyle of the proximal tibia had been treated by curettage and iliac bone grafting without radiotherapy, a 53-year-old woman noted progressive pain and an enlarging mass in the same area.
  • Radiographs showed osteolytic change, whereas magnetic resonance imaging indicated a tumor arising at the site of the giant cell tumor and extending beyond the bone.
  • Examination of an open biopsy specimen showed a high-grade malignant fibrous histiocytoma with some areas rich in giant cells.
  • After five courses of caffeine assisted intraarterial chemotherapy, the tumor was resected with an adequate margin, and the defect was reconstructed with an implanted prosthesis of corresponding shape.
  • The resected specimen showed a good histologic response (95% tumor necrosis) to preoperative chemotherapy.
  • Caffeine potentiated chemotherapy was effective in minimizing the extent of tumor excision, in this case of high-grade malignant fibrous histiocytoma representing transformation from a benign giant cell tumor.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Transformation, Neoplastic. Giant Cell Tumor of Bone / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasms, Second Primary. Tibia
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127655.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Hsieh PC, Li KW, Sciubba DM, Suk I, Wolinsky JP, Gokaslan ZL: Posterior-only approach for total en bloc spondylectomy for malignant primary spinal neoplasms: anatomic considerations and operative nuances. Neurosurgery; 2009 Dec;65(6 Suppl):173-81; discussion 181
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior-only approach for total en bloc spondylectomy for malignant primary spinal neoplasms: anatomic considerations and operative nuances.
  • MALIGNANT PRIMARY SPINAL tumors are rare tumors that are locally invasive and can metastasize.
  • The majority of these tumors have a poor response rate to chemotherapy and conventional radiotherapy.
  • Total en bloc spondylectomy involves removal of vertebral segment(s) in whole to achieve wide tumor excision.
  • The posterior-only approach offers the advantage of achieving complete tumor excision and circumferential spinal reconstruction in a single setting.
  • In this report, we discuss the operative management of malignant primary vertebral tumors using the posterior-only approach for total en bloc spondylectomy.
  • [MeSH-minor] Adult. Arthrodesis / instrumentation. Arthrodesis / methods. Diskectomy / instrumentation. Diskectomy / methods. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / surgery. Humans. Laminectomy / instrumentation. Laminectomy / methods. Male. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934992.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


18. Bouralexis S, Clayer M, Atkins GJ, Labrinidis A, Hay S, Graves S, Findlay DM, Evdokiou A: Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. Int J Oncol; 2004 May;24(5):1263-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.
  • Chemotherapy is an established treatment modality for bone sarcomas such as osteosarcoma (OS).
  • However, the use of chemotherapy in high-grade soft tissue sarcomas remains controversial, with the most active chemotherapeutic agent, doxorubicin (DOX), reported to have a response rate of, at best only 34% and most studies reporting lower response rates.
  • Apo2L/TRAIL is a member of the tumour necrosis factor (TNF) family of cytokines and induces death of tumour cells, but not normal cells.
  • Its potent apoptotic activity is mediated through cell surface death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2.
  • We investigated the efficacy of Apo2L/TRAIL as a single agent, and in combination with clinically relevant chemotherapeutic drugs, in fresh isolates of primary malignant cells obtained from biopsy material.
  • The data presented here demonstrate that, in a range of primary bone related tumours, as well as soft tissue sarcomas, chemotherapeutic agents were only moderately effective, in terms of induction of cell death.
  • Apo2L/TRAIL alone had little or no effect on any bone-related tumour or sarcoma in culture.
  • In contrast, the combination of Apo2L/TRAIL and chemotherapeutic drugs produced a significant increase in tumour cell death, with DOX and Apo2L/TRAIL proving to be the most effective combination.
  • These data suggest the potential for Apo2L/TRAIL to increase the effectiveness of chemotherapeutic drugs in bone and soft tissue sarcomas, while perhaps concurrently allowing a reduction in the exposure to drugs such as DOX, and a consequent reduction in toxicity.
  • The synergistic action between these two different classes of agents has yet to be tested in vivo but may prove clinically relevant in the treatment of this refractive class of malignancies.
  • [MeSH-major] Bone Neoplasms / drug therapy. Doxorubicin / therapeutic use. Giant Cell Tumor of Bone / therapy. Membrane Glycoproteins / therapeutic use. Osteosarcoma / drug therapy. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins. Child. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. TNF-Related Apoptosis-Inducing Ligand. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15067350.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin
  •  go-up   go-down


19. Guo W, Tang XD, Li X, Ji T, Sun X: [The analysis of the treatment of giant cell tumor of the pelvis and sacrum]. Zhonghua Wai Ke Za Zhi; 2008 Apr 1;46(7):501-5
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis of the treatment of giant cell tumor of the pelvis and sacrum].
  • OBJECTIVE: To discuss the surgical management, local recurrence rate and complications of giant cell tumor (GCTs) of the pelvic and sacrum.
  • According to the site of the tumors on the bone, they was classified into three regions: 8 patients involved region I (ilium), 10 region II (acetabulum) and 4 region III (ischiopubic).
  • Surgical management: 2 patients received 3 times of operations and 7 underwent 2 operations.
  • There were 19 patients managed with intralesional marginal excision and 2 patients with intralesional marginal excision and adjuvant radiotherapy, another 3 patients with widely marginal excision as the treatment of sacral lesions.
  • RESULTS: One recurrent patient with the large, ragged tumor died of serious infection in 2 weeks after the second surgery.
  • One patient of malignant giant cell tumor of sacrum died at 15 months after surgery.
  • One patient with postoperation sarcoma underwent reoperation and radiotherapy but died at the 13th month.
  • One patient with sacral lesion occurred pulmonary metastases in two years after surgery, and received chemotherapy with ADM, DDP and IFO.
  • One year later there was no much change in metastatic tumor.
  • CONCLUSIONS: The treatment for GCT of the pelvic and sacrum should be more aggressive because of high incidence of local recurrence after intralesional excision.
  • Although it might induce sacral nerve deficit, widely marginal excision is the best surgical procedure because of its low recurrence rate.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Pelvic Bones. Sacrum

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785558.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Alacacioğlu A, Bengi G, Oztop I, Canda T, Balci P, Osma E, Yilmaz U: Metastasis of giant cell tumor to the breast: case report and review of the literature. Tumori; 2006 Jul-Aug;92(4):351-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of giant cell tumor to the breast: case report and review of the literature.
  • Breast cancer is the most common type of malignancy in women.
  • Metastasis of soft tissue tumors to the breast is rarely seen.
  • In particular, metastasis of a giant cell tumor to the breast has never been reported in the literature.
  • We present here a case of breast metastasis in a 44-year-old woman with a diagnosis of malignant giant cell tumor originating from the distal radius and metastatic to the lung, who had been treated with radiotherapy, surgery and chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Breast Neoplasms / secondary. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Radius
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Mammography. Mastectomy, Segmental. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036529.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


21. Koswig S, Budach V: [The role of radiotherapy in the treatment of bone neoplasms]. Chirurg; 2002 Dec;73(12):1174-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of radiotherapy in the treatment of bone neoplasms].
  • Primary malignant bone neoplasms are relatively rare.
  • The most common bone tumors are osteosarcoma,Ewing's sarcoma,chondrosarcoma, fibrosarcoma,malignant fibrous histiocytoma of bone, giant cell tumor, aneurysmal bone cyst and chordoma.
  • These tumors are generally considered to be a radioresistant entities, but it has been suggested that radiotherapy may be effective in a palliative and in some curative situations, if a sufficient dose is given to an adequate volume.
  • Only for the management of primary Ewing's sarcoma the radiation therapy is an essential part in the multimodal therapy concept.
  • The most common bone neoplasms and the role of the radiotherapy are discussed in these chapter.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Chondrosarcoma / radiotherapy. Osteosarcoma / radiotherapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Cysts, Aneurysmal / radiotherapy. Bone Cysts, Aneurysmal / surgery. Child. Child, Preschool. Chordoma / radiotherapy. Chordoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Dose Fractionation. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Follow-Up Studies. Giant Cell Tumors / radiotherapy. Giant Cell Tumors / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Palliative Care. Postoperative Care. Radiotherapy Dosage. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491046.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


22. Lachat MR, Weber M, Cserhati MD, Honegger HP, von Hochstetter AR: [Giant cell tumor of bone with rapid malignant course]. Orthopade; 2004 Mar;33(3):344-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of bone with rapid malignant course].
  • [Transliterated title] Riesenzelltumor des Knochens mit rapid malignem Verlauf.
  • The case of a 28-year-old male patient with a locally aggressive lesion of the distal tibia is presented.
  • Following the diagnosis of giant cell tumor of bone (GCT) on biopsy and curettage, a rapid malignant course was observed with recurrence 2.5 months later.
  • Following initial chemotherapy according to the COSS protocol and later with carboplatin and VP-16, therapy was changed to Adriamycin and later gemcitabine due to progressive disease.
  • The malignant nature of the tumor was not detected in the initial pathologic examinations.
  • Review of the pathologic material provided histologic clues permitting the diagnosis of a primary malignant GCT with a fibrohistiocytic/fibrosarcomatous component.
  • Malignancy in a giant cell tumor is a much debated diagnostic dilemma when a frank sarcomatous component is lacking.
  • Cytologic atypias and flame-like tufts of infiltration of soft tissue are important clues.
  • Surgical treatment should be commensurate.
  • [MeSH-major] Ankle Joint. Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Tibia
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Transplantation. Curettage. Disease Progression. Fatal Outcome. Humans. Lung / pathology. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • [Cites] J Bone Joint Surg Am. 1997 Feb;79(2):259-62 [9052550.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):541-6 [2554283.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] J Bone Joint Surg Am. 1992 Jul;74(6):930-4 [1634584.001]
  • [Cites] J Bone Joint Surg Am. 1989 Jun;71(5):757-61 [2732265.001]
  • [Cites] Clin Orthop Relat Res. 2000 Dec;(381):185-91 [11127655.001]
  • [Cites] J Bone Joint Surg Br. 1972 May;54(2):216-29 [5034822.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):955-60 [3872579.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • (PMID = 15007559.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Bertoni F, Bacchini P, Staals EL: Malignancy in giant cell tumor. Skeletal Radiol; 2003 Mar;32(3):143-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy in giant cell tumor.
  • Malignant giant cell tumor is a confusing term that in the past has been used to describe different types of giant cell-rich tumors.
  • We consider two types of malignancy in giant cell tumor of bone: "primary" when it arises in juxtaposition to a benign giant cell tumor and 'secondary' when it arises at the site of a previously treated giant cell tumor.
  • Here we present a case of primary malignancy in giant cell tumor that was initially not recognized as a malignancy.
  • On radiography and histology of frozen sections the lesion had the appearance of a conventional giant cell tumor of bone.
  • After curettage, the permanent histology slides showed areas of highly malignant osteosarcoma juxtaposed to areas of benign giant cell tumor.
  • The patient was treated with chemotherapy and wide resection of the tumor.
  • [MeSH-major] Femoral Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Osteosarcoma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12605278.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Fu M, Shen JN, Huang G, Wang J, Fu QZ, Yang ZH: [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases]. Ai Zheng; 2007 Nov;26(11):1237-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases].
  • BACKGROUND & OBJECTIVE: Malignant tumors around the pelvis and acetabulum locate deeply with complex anatomic structure, meanwhile, the resection area involves the weight-loading alignment.
  • Therefore, tumor resection plus acetabular joint reconstruction is a complicated operation.
  • This study was to summarize our experience of tumor resection plus prosthesis reconstruction of the acetabular joint for this disease.
  • METHODS: Clinical data of 12 patients with malignant tumors around the pelvis and acetabulum, treated with tumor resection plus prosthesis reconstruction of the acetabular joint from 1995 to 2006, were reviewed.
  • The characteristics of the operating for this disease were analyzed in terms of preoperative preparation, operating strategy, prosthesis design, operating procedure, acetabular reconstruction, and postoperative rehabilitation.
  • RESULTS: The patients were followed for 8-86 months, with a median of 46 months.
  • Of the 4 patients with tumor relapse, 2 osteosarcoma patients died of lung metastasis at 15 months and 22 months after operation; 1 chondrosarcoma patient relapsed locally at 26 months after operation and died at 38 months after operation; 1 giant cell tumor patient relapsed locally at 13 months after operation and was treated by clearance of focal lesion, and survived tumor-freely till the end of follow-up.
  • The other 9 patients still survived tumor-freely till the end of follow-up.
  • CONCLUSIONS: Pelvic tumor resection and prosthesis reconstruction of the acetabular joint has the characteristics of difficulty and high-risk.
  • For bone tumors with relatively low malignancy, this surgical treatment is an ideal option.
  • [MeSH-major] Acetabulum / surgery. Arthroplasty, Replacement, Hip / methods. Bone Neoplasms / surgery. Chondrosarcoma / surgery. Hip Prosthesis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Osteosarcoma / drug therapy. Osteosarcoma / secondary. Osteosarcoma / surgery. Pelvic Bones / surgery. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Shi X, Wu S, Zhao J: [Limb salvage with osteoarticular allografts after resection of proximal tibia bone]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):966-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limb salvage with osteoarticular allografts after resection of proximal tibia bone].
  • METHODS: From 1998 to 2003, 15 patients (7 males, 8 females; aged 14-56 yr. average 33) with bone tumor of the proximal tibia underwent osteoarticular allografts. among whom 7 had progressive giant cell tumor without any previous chemotherapy; 8 had malignant tumor with previous chemotherapy, including 6 patients with osteosarcoma, 1 with spindle cell sarcoma, and 1 with malignant fibrous histiocytoma.
  • RESULTS: The follow-up for an average of 21 months (range, 3-58 months) revealed that among the 8 patients with malignant tumor of the proximal tibia undergoing chemotherapy, 5 had union of the bone, 3 had no union of the bone; among the 3 patients, 2 had a complication of infection and 1 had a local recurrence.
  • According to the Mankin score, 2 patients had a perfect result, 2 good, 1 fair, and 3 poor, with a 50% effectiveness rate.
  • Among the 7 patients with progressive giant cell tumor at the upper part of the tibia, none had infection or local recurrence, but 2 had nonunion of the bone and 2 had joint instability, aided by the knee-aiding system.
  • According to the Mankin score, 3 patients had a perfect result, 2 good, and 2 fair, with a 71% effectiveness rate.
  • CONCLUSION: The osteoarticular allograft of the proximal tibia has many advantages in spite of a relatively high rate of complications, and it is the limb salvage of choice for the progressive benign or malignant bone tumors of the proximal tibia.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Tibia
  • [MeSH-minor] Adolescent. Adult. Bone Transplantation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140064.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


26. Manili M, Fredella N, Santori FS: Shoulder prosthesis in reconstruction of the scapulohumeral girdle after wide resection to treat malignant neoformation of the proximal humerus. Chir Organi Mov; 2002 Jan-Mar;87(1):25-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shoulder prosthesis in reconstruction of the scapulohumeral girdle after wide resection to treat malignant neoformation of the proximal humerus.
  • Progress in preoperative chemotherapy and radiation therapy, both intra- and postoperative, has in time allowed for an increase in indications for shoulder implant surgery in malignant tumors, thus drastically reducing the number of amputations.
  • The use of prostheses, particularly those of the more recent generation, respond to the needs to overcome the limits of loss of movement, as long as good anatomical reconstruction of the soft tissues, the premise for good functional and cosmetic recovery, is also possible.
  • This type of prosthesis has surpassed custom made prostheses in terms of simplicity, adaptability and economy.
  • The main problem in reconstruction with a prosthesis is the quantity of residual muscular tissue (deltoideus, extrarotators) and the stabilization system of the same to the prosthesis in order to avoid dislocation, which constitutes the main complication.
  • It is the purpose of this study to present the clinical and functional results obtained in 23 implants carried out for primary malignant neoformation of the upper limb.
  • The implants studied were of three types (custom made, modular in Cr-Co-Mb and Ti-Al-Va).
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Histiocytoma, Benign Fibrous / surgery. Humerus / surgery. Joint Prosthesis. Sarcoma / surgery. Shoulder Joint / surgery
  • [MeSH-minor] Arthrodesis. Chondrosarcoma / surgery. Follow-Up Studies. Humans. Osteosarcoma / surgery. Prosthesis Failure. Sarcoma, Ewing / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12198947.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Burnei G, Burnei C, Hodorogea D, Gavriliu S, Georgescu I, Vlad C: Osteoarticular reconstructive surgery in malignant bone tumors: the importance of external fixators. J Med Life; 2008 Jul-Sep;1(3):295-306
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoarticular reconstructive surgery in malignant bone tumors: the importance of external fixators.
  • The patients with malignant bone tumors (table 1.) were studied by sex, tumor type, location, age at the moment of diagnosis, age at the moment of the last evaluation, type of surgery, external fixator implanted, complications, results and survival period.
  • We also considered for each patient the extent of the tumor to diaphysis, soft tissue involvement, involvement of physis and epiphyseal invasion, articular extent, vessels and nerves invasion, presence of metastases and local skin invasion.
  • The certain diagnosis was based on pathological anatomy exam, because clinical and imagistic data were not decisive in each case.
  • The conservative treatment is preferred to the amputation, which is being used in very few cases.
  • The development of reconstructive bone surgery is sustained by the possibility to delineate the tumor by diagnosis based on imaging and by the possibility to use modern preoperative and postoperative chemotherapy and radiotherapy.
  • Since then the same treatment was preferred also in malignant bone tumors, because the relapse appeared as frequent as in cases with amputation but the physical and psychological comfort made the patients to accept it readily.
  • The goal of malignant bone tumors treatment is to save the life of the patient, to preserve the affected limb, to maintain the length and function of the limb.
  • Oncologic surgery consists of "en bloc" tumor resection followed by bone reconstruction or modular prosthetic replacement.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. External Fixators. Giant Cell Tumor of Bone / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Femur / surgery. Humans. Humerus / surgery. Male. Reconstructive Surgical Procedures / methods. Retrospective Studies. Sarcoma, Ewing / surgery. Tibia / surgery. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 1987;11(1):35-41 [3549587.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):51-61 [10810462.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1985;71(7):435-50 [3911313.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] J Bone Joint Surg Br. 1995 Jul;77(4):608-14 [7615607.001]
  • [Cites] Ital J Orthop Traumatol. 1975 Apr;1(1):5-22 [1067250.001]
  • [Cites] J Bone Joint Surg Am. 1988 Apr;70(4):507-16 [3281952.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):558-61 [9250738.001]
  • [Cites] J Bone Joint Surg Am. 1990 Mar;72(3):334-45 [2135632.001]
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):212-20 [11550868.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):181-96 [1884538.001]
  • [Cites] Int Orthop. 1998;22(1):27-31 [9549578.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1393-9 [4045528.001]
  • [Cites] Int Orthop. 1988;12(1):21-9 [3372098.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1978 Jan;60(1):31-40 [415064.001]
  • [Cites] Acta Orthop Scand. 1989 Apr;60(2):143-53 [2658466.001]
  • [Cites] Int Orthop. 1998;22(5):330-4 [9914940.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • (PMID = 20108507.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


28. Xu J, Sun H, Xiao Y: [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):352-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor].
  • METHODS: From January 2001 to September 2005, 13 patients (8 males, 5 females; aged 14-57 years, averaged 29.7 years) suffering from the proximal tibial tumors were treated with a limb-salvage operation.
  • Among them, there were 4 patients with osteosarcoma, 6 with malignant fibrous histocytoma, 1 with malignant giant cell tumor, 1 with synovial sarcoma, and 1 with Ewing's sarcoma.
  • One or two cycles of neoadjuvant chemotherapy were used to each of the patients before operation.
  • All of the patients underwent the medial head of the gastrocnemius muscle flap transposition to reconstruct the soft tissues after resection of the tumors and reconstruction of the bone defect by prothesis or bone-graft or the two methods combined.
  • 2 months) in all the patients revealed that. there was no flap necrosis, no skin necrosis at the incision margins, and no infection or fracture of the implanted bone.
  • The patient with malignant fibrous histocytoma died of systemic metastasis 20 months after operation.
  • The patient with Ewing's sarcoma had a local tumor recurrence 18 months after operation; though treated with the focal cleaning and the bone cement filling, the patient still developed lung metastasis of the tumor 26 months after operation.
  • The patient with osteosarcoma underwent amputation 12 months after operation because of the tumor recurrence.
  • According to the function assessment by the Mankin system, there were 6 patients who had an excellent result, 4 had a good result, and 3 had a poor result, with a satisfaction rate of 77%.
  • CONCLUSION: The flap transposition of the medial head of the gastrocnemius muscle can reconstruct the soft tissue defect, decrease the local complication rate and improve the clinical outcome of the limb salvage for the proximal tibia malignant tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Soft Tissue Injuries / surgery. Surgical Flaps / blood supply. Tibia
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Knee. Bone Transplantation / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546876.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement